Starting Ozempic: what TikTok gets right and wrong about week-by-week GLP-1 side effects

What did @notsofatamyy actually say?

Honestly? Not much that we can fact-check. The caption tells the story here, because the actual video audio is incoherent, appearing to be either a music overlay or a completely unrelated audio track. The caption claims she started at 0.25 mg in week one, felt little effect, then moved to 0.4 mg in week two, which she says "rocked my world" with food aversions and appetite suppression. That escalation claim is where things get medically interesting, and a little concerning.

Since the transcript contains no medical content, this fact-check focuses on the caption's specific claims about dosing timing and side effect onset. The caption cuts off mid-sentence, so we're working with incomplete information. That's not ideal for a health claim that 5,700 people have already seen.

Does the science back this up?

The general arc she describes, minimal effects at the starting dose and stronger side effects after an increase, is consistent with how semaglutide actually works. The 0.25 mg starting dose in the SUSTAIN trial program (Aroda et al., 2017, Diabetes Care) was explicitly designed as a tolerability dose, not a therapeutic one. Patients weren't expected to feel much. So week one being uneventful tracks.

Where it gets complicated is the 0.4 mg figure. Ozempic's approved titration schedule goes 0.25 mg, then 0.5 mg. There is no 0.4 mg standard dose in the semaglutide prescribing information. This suggests she may be on a compounded version, where doses can differ from brand-name products, or she misremembered or misstated the dose. Either way, the specific number deserves scrutiny. Research from Davies et al. (2021, The Lancet) confirmed that GLP-1 side effects including nausea and appetite suppression typically intensify with dose escalation, so the symptom pattern she describes is real. The exact dose she names is not standard.

What did they get wrong (or right)?

Credit where it's due: the general experience she describes matches what clinical data shows. Food aversions and reduced appetite after a dose increase are well-documented. A 2022 analysis by Rubino et al. in Obesity reported that nausea occurred in roughly 44% of patients on 2.4 mg semaglutide, with rates climbing during titration periods specifically. She got the pattern right.

What she got wrong, or at minimum unclear, is the dose. 0.4 mg is not a standard Ozempic titration step. If she's on compounded semaglutide, it's worth stating that plainly, because compounded and brand-name semaglutide are not equivalent products and should not be treated as interchangeable. The FDA has flagged concerns about compounded semaglutide dosing accuracy. Describing a non-standard dose without that context can mislead viewers into thinking their own titration should mirror hers, which could push someone to escalate faster than their prescriber intended.

What should you actually know?

GLP-1 receptor agonist titration schedules exist for a reason. The slow ramp-up is not a marketing choice. It reduces the rate of gastrointestinal side effects that are the primary reason people discontinue therapy. A 2023 real-world study by Wilding et al. in Diabetes, Obesity and Metabolism found that discontinuation rates in the first 12 weeks were significantly tied to GI tolerability, not effectiveness.

If you're starting semaglutide, your dose and schedule should come from your prescriber, not from a TikTok caption. Week-by-week diaries can be genuinely useful for normalizing the experience, but they can also create false benchmarks. Someone watching this and thinking they should feel dramatic effects by week two, or that 0.4 mg is a real titration point, is walking away with potentially inaccurate expectations. The video's value is in the lived experience framing. The specific numbers need verification from a licensed provider.

The bottom line

The side effect story she tells is plausible and supported by clinical literature. The dose she names doesn't match standard Ozempic titration. That gap matters.

• Starting semaglutide with minimal effects at 0.25 mg is expected and documented.
• Side effect intensification after dose escalation is real and well-studied.
• 0.4 mg is not a standard Ozempic dose step. This may indicate compounded semaglutide, which carries different regulatory and accuracy considerations.
• Compounded semaglutide is not the same as brand-name Ozempic or Wegovy. Dosing, purity, and formulation differ.
• Personal timelines on GLP-1 therapy vary significantly. Using someone else's week-by-week experience as a template for your own can lead to premature dose escalation or unnecessary anxiety.